Literature DB >> 18497416

Incorporating considerations of resources use into grading recommendations.

Gordon H Guyatt1, Andrew D Oxman, Regina Kunz, Roman Jaeschke, Mark Helfand, Alessandro Liberati, Gunn E Vist, Holger J Schünemann.   

Abstract

Mesh：

Year:  2008        PMID： 18497416      PMCID： PMC2394579          DOI： 10.1136/bmj.39504.506319.80

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  11 in total

1.  Evaluation of conflict of interest in economic analyses of new drugs used in oncology.

Authors:  M Friedberg; B Saffran; T J Stinson; W Nelson; C L Bennett
Journal:  JAMA       Date:  1999-10-20       Impact factor: 56.272

2.  Opportunity costs in modern medicine.

Authors:  L B Russell
Journal:  Health Aff (Millwood)       Date:  1992       Impact factor: 6.301

3.  Economic foundations of cost-effectiveness analysis.

Authors:  A M Garber; C E Phelps
Journal:  J Health Econ       Date:  1997-02       Impact factor: 3.883

Review 4.  Users' guide to detecting misleading claims in clinical research reports.

Authors:  Victor M Montori; Roman Jaeschke; Holger J Schünemann; Mohit Bhandari; Jan L Brozek; P J Devereaux; Gordon H Guyatt
Journal:  BMJ       Date:  2004-11-06

Review 5.  Addressing resource allocation issues in recommendations from clinical practice guideline panels: suggestions from an American College of Chest Physicians task force.

Authors:  Gordon Guyatt; Michael Baumann; Stephen Pauker; Jonathan Halperin; Janet Maurer; Douglas K Owens; Anna N A Tosteson; Brian Carlin; David Gutterman; Martin Prins; Sandra Zelman Lewis; Holger Schünemann
Journal:  Chest       Date:  2006-01       Impact factor: 9.410

Review 6.  What is "quality of evidence" and why is it important to clinicians?

Authors:  Gordon H Guyatt; Andrew D Oxman; Regina Kunz; Gunn E Vist; Yngve Falck-Ytter; Holger J Schünemann
Journal:  BMJ       Date:  2008-05-03

Review 7.  Interpretation of cost-effectiveness analyses.

Authors:  D K Owens
Journal:  J Gen Intern Med       Date:  1998-10       Impact factor: 5.128

8.  Comparing benefits and harms: the balance sheet.

Authors:  D M Eddy
Journal:  JAMA       Date:  1990-05-09       Impact factor: 56.272

9.  Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial.

Authors:  Douglas Altman; Guillermo Carroli; Lelia Duley; Barbara Farrell; Jack Moodley; James Neilson; David Smith
Journal:  Lancet       Date:  2002-06-01       Impact factor: 79.321

10.  Cost-effectiveness of prophylactic magnesium sulphate for 9996 women with pre-eclampsia from 33 countries: economic evaluation of the Magpie Trial.

Authors:  Judit Simon; Alastair Gray; Lelia Duley
Journal:  BJOG       Date:  2006-02       Impact factor: 6.531
View more
  91 in total

1.  Canadian Task Force on Preventive Health Care: we're back!

Authors:  Richard Birtwhistle; Kevin Pottie; Elizabeth Shaw; James A Dickinson; Paula Brauer; Martin Fortin; Neil Bell; Harminder Singh; Marcello Tonelli; Sarah Connor Gorber; Gabriela Lewin; Michel Joffres; Patricia Parkin
Journal:  Can Fam Physician       Date:  2012-01       Impact factor: 3.275

2.  Utilities and QALYs in health economic evaluations: glossary and introduction.

Authors:  Gianni Virgili; Daniela Koleva; Livio Garattini; Rita Banzi; Gian Franco Gensini
Journal:  Intern Emerg Med       Date:  2010-07-06       Impact factor: 3.397

3.  Diagnosis and management of iliofemoral deep vein thrombosis: clinical practice guideline.

Authors:  David Liu; Erica Peterson; James Dooner; Mark Baerlocher; Leslie Zypchen; Joel Gagnon; Michael Delorme; Chad Kim Sing; Jason Wong; Randolph Guzman; Gavin Greenfield; Otto Moodley; Paul Yenson
Journal:  CMAJ       Date:  2015-09-28       Impact factor: 8.262

4.  Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Gordon H Guyatt; Susan L Norris; Sam Schulman; Jack Hirsh; Mark H Eckman; Elie A Akl; Mark Crowther; Per Olav Vandvik; John W Eikelboom; Marian S McDonagh; Sandra Zelman Lewis; David D Gutterman; Deborah J Cook; Holger J Schünemann
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 5.  Rating the quality of evidence and the strength of recommendations using GRADE.

Authors:  Steven E Canfield; Philipp Dahm
Journal:  World J Urol       Date:  2011-03-09       Impact factor: 4.226

6.  [Clinical practice guideline on the management of patients with dyspepsia. Update 2012].

Authors:  Javier P Gisbert; Xavier Calvet; Juan Ferrándiz; Juan Mascort; Pablo Alonso-Coello; Mercè Marzo
Journal:  Aten Primaria       Date:  2012-10-01       Impact factor: 1.137

7.  Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry.

Authors:  M Cárdenas; S de la Fuente; P Font; M C Castro-Villegas; M Romero-Gómez; D Ruiz-Vílchez; J Calvo-Gutiérez; A Escudero-Contreras; M A Casado; J R Del Prado; E Collantes-Estévez
Journal:  Rheumatol Int       Date:  2016-02       Impact factor: 2.631

8.  Challenges in developing evidence-based recommendations using the GRADE approach: the case of mental, neurological, and substance use disorders.

Authors:  Corrado Barbui; Tarun Dua; Mark van Ommeren; M Taghi Yasamy; Alexandra Fleischmann; Nicolas Clark; Graham Thornicroft; Suzanne Hill; Shekhar Saxena
Journal:  PLoS Med       Date:  2010-08-31       Impact factor: 11.069

9.  The GRADE approach for assessing new technologies as applied to apheresis devices in ulcerative colitis.

Authors:  Nora Ibargoyen-Roteta; Iñaki Gutiérrez-Ibarluzea; Rosa Rico-Iturrioz; Marta López-Argumedo; Eva Reviriego-Rodrigo; Jose Luis Cabriada-Nuño; Holger J Schünemann
Journal:  Implement Sci       Date:  2010-06-16       Impact factor: 7.327

10.  SUPPORT Tools for evidence-informed health Policymaking (STP) 16: Using research evidence in balancing the pros and cons of policies.

Authors:  Andrew D Oxman; John N Lavis; Atle Fretheim; Simon Lewin
Journal:  Health Res Policy Syst       Date:  2009-12-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.